1. Academic Validation
  2. Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene

Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene

  • J Biol Chem. 2006 Apr 14;281(15):10567-76. doi: 10.1074/jbc.M513397200.
Carlo Iavarone 1 Mario Acunzo Francesca Carlomagno Annunziata Catania Rosa M Melillo Stella M Carlomagno Massimo Santoro Mario Chiariello
Affiliations

Affiliation

  • 1 Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy.
Abstract

Mitogen-activated protein (MAP) kinases have a central role in several biological functions, including cell adhesion and spreading, chemotaxis, cell cycle progression, differentiation, and Apoptosis. Extracellular signal-regulated kinase 8 (ERK8) is a large MAP kinase whose activity is controlled by serum and the c-Src non-receptor tyrosine kinase. Here, we show that RET/PTC3, an activated form of the RET proto-oncogene, was able to activate ERK8, and we demonstrate that such MAP kinase participated in RET/PTC3-dependent stimulation of the c-Jun promoter. By using RET/PTC3 molecules mutated in specific tyrosine autophosphorylation sites, we characterized Tyr(981), a known binding site for c-Src, as a major determinant of RET/PTC3-induced ERK8 activation, although, surprisingly, the underlying mechanism did not strictly depend on the activity of Src. In contrast, we present evidence that RET/PTC3 acts on ERK8 through Tyr(981)-mediated activation of c-Abl. Furthermore, we localized the region responsible for the modulation of ERK8 activity by the RET/PTC3 and Abl oncogenes in the ERK8 C-terminal domain. Altogether, these results support a role for ERK8 as a novel effector of RET/PTC3 and, therefore, RET biological functions.

Figures